Show simple item record

dc.contributor.authorÇİFTÇİLER, Rafiye
dc.contributor.authorÇİFTÇİLER, Erdinç
dc.contributor.authorHAZNEDAROĞLU, İbrahim
dc.date.accessioned2021-06-03T05:20:15Z
dc.date.available2021-06-03T05:20:15Z
dc.date.issued2019
dc.identifier.issn2148-5046
dc.identifier.urihttp://dx.doi.org/10.5606/ArchRheumatol.2019.7361
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974380/
dc.identifier.urihttp://hdl.handle.net/11655/24013
dc.description.abstractAnkaferd hemostat (Ankaferd Blood Stopper; ABS) is a pro-hemostatic agent affecting erythrocytes. In this article, we report a 50-year-old male patient who presented with a non-healing leg ulcer for one year. He had a past medical history of Behçet’s disease (BD) diagnosed at the age of 29 and therapy was started. Patient's leg ulcer did not respond to any treatment. Topical ABS was applied to the patient's leg ulcer daily. Our experience suggested that local treatment of ABS can be a potentially successful therapy for the management of intractable or incurable chronic ulcers in patients with BD or for other ischemic or vasculitic skin problems.
dc.language.isoen
dc.relation.isversionof10.5606/ArchRheumatol.2019.7361
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEffective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet’S Disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalArchives Of Rheumatology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume34
dc.identifier.issue4
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 United States
Except where otherwise noted, this item's license is described as Attribution 4.0 United States